<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852021000500002</article-id>
<article-id pub-id-type="doi">10.48193/revistamexicanadeurologa.v81i5.803</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Incidencia y agresividad del cáncer de próstata por antígeno prostático específico y tacto rectal en el Hospital Regional &#8220;Lic. Adolfo López Mateos&#8221;]]></article-title>
<article-title xml:lang="en"><![CDATA[Incidence and aggressiveness of prostate cancer due to prostate specific antigen and digital rectal examination in the Hospital Regional &#8220;Lic. Adolfo López Mateos"]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Lastra]]></surname>
<given-names><![CDATA[Karen Yadhira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Cortéz]]></surname>
<given-names><![CDATA[Ángel Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Ávalos]]></surname>
<given-names><![CDATA[Raymundo Moisés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Villa]]></surname>
<given-names><![CDATA[Patricio Cruz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital Regional &#8220;Lic. Adolfo López Mateos&#8221; ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2021</year>
</pub-date>
<volume>81</volume>
<numero>5</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852021000500002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852021000500002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852021000500002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Determinar la sensibilidad y especificidad del tacto rectal del médico residente para detectar cáncer de próstata y la incidencia de la agresividad por APE en el Hospital Regional &#8220;Lic. Adolfo López Mateos&#8221; del ISSSTE, en pacientes sometidos a biopsia transrectal de próstata.  Diseño:  Estudio transversal, analítico y descriptivo. Se incluyeron 377 pacientes, a los cuales se les realizó APE, TR y BTRP de 2017 a 2020, por residentes del segundo año de urología.  Resultados:  La edad promedio fue de 66.2 años, la mediana de APE de 10.45ng/mL y el volumen de la próstata promedio fue de 71.1cc, utilizando un ultrasonido transrectal. La sensibilidad y especificidad del tacto rectal en pacientes con APE de 4-9.9ng/mL fue de 27% y 90.4% respectivamente, en pacientes con APE de 10-19.9ng/mL, fue de 49.2% y 85.9% y en pacientes con APE mayor de 20ng/mL fue de 73.8% y 73.1%.  Limitaciones del estudio:  Habilidad del tacto rectal del médico residente, se encuentra en formación y desarrollando destrezas, entre ellas detectar alteraciones en el tacto rectal.  Originalidad:  De acuerdo con nuestra búsqueda no encontramos datos sobre la sensibilidad y especificidad en nuestro país del tacto rectal por el médico residente en un Hospital escuela. Por lo que, es una buena aportación conocer esta información cuando nos encontramos como médicos residentes en formación.  Conclusiones:  En nuestro estudio observamos, que al aumentar el APE incrementa la sensibilidad del TR, aumentando así, las posibilidades de obtener un RHP positivo a malignidad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  To determine the sensitivity and specificity of the resident physician's digital rectal examination to detect prostate cancer and the incidence of aggression due PSA at the Hospital Regional &#8220;Lic. Adolfo Lopez Mateos&#8221; ISSSTE, in patients undergoing transrectal prostate biopsy.  Design:  Cross-sectional, analytical, descriptive study. 377 patients who underwent PSA, RT and TRBP from 2017 to 2020 were included, these was made by residents of the second year of Urology.  Results:  The average age was 66.2 years, the median PSA 10.45ng/mL, and the average prostate volume was 71.1cc, we used transrectal ultrasound. The sensitivity and specificity of digital rectal examination in patients with PSA of 4-9.9ng/mL was 27% and 90.4% respectively, in patients with PSA of 10-19.9ng/mL, it was 49.2% and 85.9% and in patients with PSA greater than 20ng/mL was 73.8% and 73.1%.  Limitations of the study:  Rectal examination skills of the resident physician, is in training and developing skills, including detecting alterations in the digital rectal examination.  Originality:  According to our search, we did not find data on the sensitivity and specificity in our country of digital rectal examination by the resident physician in a teaching hospital. So it is a good contribution to know this information when we are as resident doctors in training.  Conclusions:  In our study, we observed that increasing the PSA increased the sensitivity of the RT, thus increasing the chances of obtaining a positive RHP for malignancy.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
<kwd lng="en"><![CDATA[prostate]]></kwd>
<kwd lng="en"><![CDATA[biopsy]]></kwd>
<kwd lng="en"><![CDATA[digital rectal]]></kwd>
<kwd lng="es"><![CDATA[Cáncer]]></kwd>
<kwd lng="es"><![CDATA[próstata]]></kwd>
<kwd lng="es"><![CDATA[biopsia]]></kwd>
<kwd lng="es"><![CDATA[tacto rectal]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wein]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kolon]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
</person-group>
<source><![CDATA[Campbell-Walsh Urology]]></source>
<year>2020</year>
<edition>12th</edition>
<page-range>634</page-range><publisher-loc><![CDATA[Estados Unidos ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez López]]></surname>
<given-names><![CDATA[H M]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de Uroonco]]></source>
<year>2016</year>
<edition>3rd</edition>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Cuellar Ayala]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[Guidelines Prostate Cancer Early Detection]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Estados Unidos ]]></publisher-loc>
<publisher-name><![CDATA[American Cancer Society]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>American Urological Association</collab>
<source><![CDATA[Early Detection of Prostate Cancer]]></source>
<year>2016</year>
<publisher-name><![CDATA[American Urological Association]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Der Cruijsen-Koeter]]></surname>
<given-names><![CDATA[Iw.]]></given-names>
</name>
<name>
<surname><![CDATA[Wildhagen]]></surname>
<given-names><![CDATA[Mf.]]></given-names>
</name>
<name>
<surname><![CDATA[De Koning]]></surname>
<given-names><![CDATA[Hj.]]></given-names>
</name>
<name>
<surname><![CDATA[Schröder]]></surname>
<given-names><![CDATA[Fh]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The value of current diagnostic tests in prostate cancer screening]]></article-title>
<source><![CDATA[BJU International]]></source>
<year>2001</year>
<volume>88</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>458-66</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruno]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Armenakas]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Fracchia]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of Prostate Volume and Percent Free Prostate Specific Antigen on Prostate Cancer Detection in Men With a Total Prostate Specific Antigen of 2.6 to 10.0 ng/ml]]></article-title>
<source><![CDATA[Journal of Urology]]></source>
<year>2007</year>
<volume>177</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1741-4</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spurgeon]]></surname>
<given-names><![CDATA[SEF]]></given-names>
</name>
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[Y-C]]></given-names>
</name>
<name>
<surname><![CDATA[Rivadinera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beer]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Garzotto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classification and Regression Tree Analysis for the Prediction of Aggressive Prostate Cancer on Biopsy]]></article-title>
<source><![CDATA[Journal of Urology]]></source>
<year>2006</year>
<volume>175</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>918-22</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gjengst]]></surname>
<given-names><![CDATA[ØP]]></given-names>
</name>
<name>
<surname><![CDATA[Paus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Halvorsen]]></surname>
<given-names><![CDATA[OJ]]></given-names>
</name>
<name>
<surname><![CDATA[Eide]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Akslen]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Wentzel-Larsen]]></surname>
<given-names><![CDATA[Tore]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study]]></article-title>
<source><![CDATA[Journal of Urology]]></source>
<year>2005</year>
<volume>173</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>425-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmitges]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trinh]]></surname>
<given-names><![CDATA[Q-D]]></given-names>
</name>
<name>
<surname><![CDATA[Walz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Graefen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgery for high-risk localized prostate cancer]]></article-title>
<source><![CDATA[Ther Adv Urol]]></source>
<year>2011</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>173-82</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ørsted]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Bojesen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Nordestgaard]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2011</year>
<volume>60</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>691-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>European Association of Urology</collab>
<source><![CDATA[Guidelines on Prostate Cancer]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Centro de Investigación en Salud Poblacional</collab>
<source><![CDATA[Mortalidad por cáncer de próstata en México a lo largo de tres décadas]]></source>
<year>2020</year>
<publisher-name><![CDATA[Instituto Nacional De Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<collab>American Cancer Society</collab>
<source><![CDATA[Pruebas de detección para el cáncer de próstata]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[LCS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínicas al tacto rectal y niveles de APE, comparados conresultado histopatológico en BTRUS]]></article-title>
<source><![CDATA[Bol Col Mex Urol]]></source>
<year>2018</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>70-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palsdottir]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nordström]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Aly]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lindberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Clements]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Egevad]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study]]></article-title>
<source><![CDATA[PLOS ONE]]></source>
<year>2019</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
